

This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims:

Claims 1 to 30 (Cancel)

31. (New) An ophthalmic, aqueous liquid composition suitable for topical application to an eye comprising an aqueous liquid, a therapeutically effective amount of prednisolone acetate and a cyclodextrin derivative, the ophthalmic composition being present as a solution.

32. (New) The ophthalmic composition of claim 31 wherein the cyclodextrin derivative is present in an amount effective to increase the apparent solubility of the prednisolone acetate or to enhance the stability of the prednisolone acetate in the composition or to reduce unwanted side effects of the prednisolone acetate.

33. (New) The ophthalmic composition of claim 31 which has an ophthalmically acceptable tonicity level.

34. (New) The ophthalmic composition of claim 31 which has an ophthalmically acceptable pH.

35. (New) The ophthalmic composition of claim 31 which further comprises at least one of an effective amount of a buffer component, an effective amount of a tonicity component and an effective amount of a preservative component.

36. (New) The ophthalmic composition of claim 31 which further comprises an effective amount of a preservative component

37. (New) The ophthalmic composition of claim 36 wherein the preservative component is a chlorite.

38. (New) The ophthalmic composition of claim 37 wherein the chlorite is stabilized chlorine dioxide.

39. (New) The ophthalmic composition of claim 31 wherein the cyclodextrin derivative is selected from the group consisting of derivatives of α -cyclodextrin, derivatives of β -cyclodextrin, derivatives of γ -cyclodextrin, carboxymethyl- β -cyclodextrin, carboxymethyl-ethyl- β -cyclodextrin, diethyl- β -cyclodextrin, dimethyl- β -cyclodextrin, methyl- β -cyclodextrin, random methyl- β -cyclodextrin, glucosyl- β -cyclodextrin, maltosyl- β -cyclodextrin, hydroxyethyl- β -cyclodextrin, hydroxypropyl- β -cyclodextrin, sulfobutylether- β -cyclodextrin, and the like and mixtures thereof.

40. (New) The ophthalmic composition of claim 31 wherein the cyclodextrin derivative is sulfobutylether β -cyclodextrin.

41. (New) A method of treating an eye comprising topically applying a therapeutically effective amount of the ophthalmic, aqueous liquid composition of claim 31 to an eye.

42. (New) A method of treating an eye comprising topically applying a therapeutically effective amount of the ophthalmic, aqueous liquid composition of claim 32 to an eye.

43. (New) A method of treating an eye comprising topically applying a therapeutically effective amount of the ophthalmic, aqueous liquid composition of claim 33 to an eye.

44. (New) A method of treating an eye comprising topically applying a therapeutically effective amount of the ophthalmic, aqueous liquid composition of claim 34 to an eye.

45. (New) A method of treating an eye comprising topically applying a therapeutically effective amount of the ophthalmic, aqueous liquid composition of claim 35 to an eye.

46. (New) A method of treating an eye comprising topically applying a therapeutically effective amount of the ophthalmic, aqueous liquid composition of claim 36 to an eye.

47. (New) A method of treating an eye comprising topically applying a therapeutically effective amount of the ophthalmic, aqueous liquid composition of claim 37 to an eye.

48. (New) A method of treating an eye comprising topically applying a therapeutically effective amount of the ophthalmic, aqueous liquid composition of claim 38 to an eye.

49. (New) A method of treating an eye comprising topically applying a therapeutically effective amount of the ophthalmic, aqueous liquid composition of claim 39 to an eye.

50. (New) A method of treating an eye comprising topically applying a therapeutically effective amount of the ophthalmic, aqueous liquid composition of claim 40 to an eye.